medigraphic.com

2023, Number 2

<< Back Next >>

Folia 2023; 17 (2)

Use of platelet-rich plasma in patients with melasma

Gutiérrez AEY

Language: Spanish
References: 27
Page:
PDF size: 445.95 Kb.


ABSTRACT

Introduction: In the last decade, some studies report the potential effect of platelet-rich plasma in the treatment of melasma.
Objective: To determine the clinical-therapeutic response of patients diagnosed with melasma treated with platelet-rich plasma.
Methods: An experimental, longitudinal and prospective study was conducted in the dermatology service of the Miguel Enríquez Clinical Surgical Teaching Hospital between January 2019 and December 2020.
Results: 52.2% of patients were between 30 and 39 years of age. 86.9% were women. A total of 43.5% were considered phototype III. A total of 73.9% were associated with photoexposure as a risk factor. The distribution pattern was facial center in 69.6%. In 56.5% of cases, the melasma was epidermal and of mild intensity. Response to treatment was excellent in 60.9% of patients and response time was between 4-8 weeks in 21.7%. Erythema was an adverse event of 10.9%.
Conclusions: Response to treatment was considered excellent in most patients and the time to reach it was less than eight weeks in most patients. A low incidence of adverse events was observed, demonstrating that platelet-rich plasma may be a safe and effective treatment option.


REFERENCES

  1. Rashmi S. Melasma: A monograph. 2 ed. India: Jaypee Brothers Medical Publisher; 2020. p. 7.

  2. Falabella, R. Fundamentos de Medicina/Dermatología. Melasma. 10 ed. Colombia:Corporación para investigaciones biológicas; 2017. p. 162-4.

  3. Demirkan S, Gündüz Ö, Sayan CD. Retrospective analysis of endemic melasmapatients. Dermatol Rep. 2017 [acceso 12/12/2018];9(1). Disponible en:https://www.pagepress.org/journals/index.php/dr/article/view/7027

  4. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. AnnBras Dermatol. 2014;89(5):771-82. DOI: http://dx.doi.org/10.1590/abd1806-4841.20143063

  5. Plenck JJ. Doctrina de Morbis Cutaneis. Qua hi morbi in suas classes, genera etspeciesredingtur. Vienna JF: Van Overbeke; 1776.

  6. Bolognia JL, Schaffer J, Cerroni L, editores. Dermatología. 4 ed. Barcelona: Elsevier;2018.

  7. Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. IndianDermatol Online J. 2014;5(4):426-35. DOI: http://dx.doi.org/10.4103/2229-5178.142484

  8. Gallardo Simeón IN, Sernaqué Juárez MF. Calidad de vida de los pacientes condiagnóstico de melasma atendidos en una oficina farmacéutica especializada en el distritode Jesús María periodo agosto-setiembre 2018 [Tesis]. Lima, Perú: Universidad NorbertWiener; 2019 [acceso 04/04/2021]. Disponible en:https://repositorio.uwiener.edu.pe/bitstream/handle/20.500.13053/2770/TESIS20

  9. Bhattarai S, Pradhan K, Sharma S, Rajouria EA. Clinical patterns and epidemiologicalcharacteristics of melasma in a tertiary care hospital of Nepal. Pigment Int. 2017;4:35-8.DOI: http://dx.doi.org/10.4103/2349-5847.208296

  10. Arora P, Meena N, Sharma PK, Raihan M. Impact of melasmaonquality of life inIndian patients. Pigment Int. 2017;4:92-7. DOI: http://dx.doi.org/10.4103/2349-5847.219683

  11. Uvanikoglu H, Aksoy M. Quality of life in patients with melasma in Turkish women.Dermatol Reports. 2017;9(2):7340. DOI: http://dx.doi.org/10.4081/dr.2017.7340

  12. Kothari P, Sharma YK, Patvekar MA, Gupta A. Correlating impairment of quality oflife and severity of melasma : A cross- sectional study of 141 patients. Indian J Dermatol.2018;63(4):292-6. DOI: http://dx.doi.org/10.4103/ijd.IJD_10_17

  13. Pudasaini P, Neupane S. An observational study to evaluate quality of life in patientswith melasma in a tertiary level hospital of Pokhara. Nepal Journal of Dermatology,Venereology & Leprology. 2021;19(1):37-41. DOI:http://dx.doi.org/10.3126/njdvl.v19i1.35047

  14. Palacios Rosales MP, Parra Nieto MB. Melasma y calidad de vida en pacientesembarazadas. Servicio de ginecología del Hospital Vicente Corral Moscoso. 2019 [Tesis].Cuenca, Ecuador: Universidad de Cuenca; 2020. [acceso 04/04/2021]. Disponible en:http://www.dspace.ucuenca.edu.ec/handle/123456789/34231

  15. Enríquez Núñez M. Determinación de la eficacia despigmentante de dos productoscosméticos elaborados uno con arbutina y el otro con una combinación de arbutina ypteriasterna, en pacientes con melasma de la Fundación Ecuatoriana de la Psoriasis [Tesisde Maestría en Ciencias y Tecnologías Cosméticas]. Quito, Ecuador: Universidad Politécnica Salesiano; 2015. [acceso 04/04/2021]. Disponible en:http://www.dspace.ups.edu.ec/handle/123456789/9378

  16. Medina Arango AP, Valencia Quintero LJ, Arredondo Ossa MI. Evaluación de laeficacia de un producto despigmentante en gel en voluntarios diagnosticados conmelasma. Rev CES Med. 2015 [acceso 12/12/2018];29(1):7-22. Disponible en:http://www.scielo.org.co/scielo.php?script=sci_arttex&pid=S0120-87052015000100002

  17. França Holmo N, Brotto Ramos G, Salomão H, Werneck RI, Távora Mira M, BartoliMiot LD, et al. Complex segregation analysis of facial melasma in Brazil: evidence for agenetic susceptibility with a dominant pattern of segregation. Archives of DermatologicalResearch 2018;310:827-31. DOI: http://dx.doi.org/10.1007/s00403-018-1861-5

  18. Barbieri D′Elia MP, Brandao MC, Ribeiro de Andrade Ramos B, Guimaraes da SilvaM, Bartoli Miot LD, Batista Dos Santos SE, et al. African ancestry is associated withfacial melasma in women: a cross-sectional study. BMC Medical Genetics. 2017;18:17.DOI: http://dx.doi.org/10.1186/s12881-017-0378-7

  19. Mahmood K, Nadeem M, Aman S, Hameed A, Kazmi AH. Role of estrogen,progesterone and prolactin in the etiopathogenesis of melasma in females. J Pak AssocDermatol. 2011 [acceso 04/12/2018];21(4):241-7. Disponible en:http://www.jpad.com.pk/index.php/jpad/article/view/483

  20. Karn D, Subedi A. Clinico-etiological profile of melasma among female healthworkers in a tertiary care center of Central Nepal. A cross sectional study. KathmanduUniv Med J. 2017;58(2):160-3.

  21. Mahdalena Jusuf NK, Putra IB. Melasma characteristic in hormonal contraceptiveacceptors at Kelurahan Mangga Kecamatan Medan Tuntungan, Medan-Indonesia. BaliMedical Journal. 2018;7(3):645-9. DOI: http://dx.doi.org/10.15562/bmj.v7i3.1000

  22. López Valdés EA. Calidad de vida en las pacientes con melasma en San JuanOstuncalco, Quetzaltenango, Guatemala, junio 2017 [tesis de grado en línea]. Ciudad deGuatemala, Guatemala: Universidad Rafael Landívar; 2017. [acceso 04/04/2021].Disponible en:http://www.recursosbiblio.url.edu.gt/tesisjrcd/2017/09/18/L25C325B3pez-Elmer.pdf

  23. Krupa Shankar DSR, Somani VK, Kohli M, Sharad J, Ganjoo A, Kandhari S, et al. Across-sectional, multicentric clinico-epidemiological study of melasma in India.Dermatol Ther (Heidelb). 2014;4:71-81. DOI: http://dx.doi.org/10.1007/s13555-014-0046-1

  24. Handel AC, Bartoli LD, Amante Miot H. Melasma: a clinical and epidemiologicalreview. An. Bras. Dermatol. 2014 [acceso 12/12/2018]89(5). Disponible en:https://www.scielo.br/j/abd/a/WPYDvDFnT6JrMDr9ZgtGkxJ/#

  25. Faiz F, Sahehzad A, Farooq R, Mufti S, Nasir A, Ahmad TJ. Efficacy of platelet-richplasma in the treatment of melasma: a pilot study. Journal of Pakistan Association ofDermatologists. 2017 [acceso 10/12/2018];28(3):348-53. Disponible en:https://www.jpad.com.pk/index.php/jpad/article/download/1268/1156/2743

  26. Hofny ERM, Abdel-Motaleb AA, Ghazally A, Ahmed AM, Hussein MR. Platelet richplasma is a useful therapeutic option in melasma. J Dermatol Treat. 2018. DOI:http://dx.doi.org/10.1080/09546634.2018.1524821

  27. Boparai AS, Bhale G, Brar S. Evaluation of therapeutic outcome of transepidermaladministration of platelet-rich plasma with micro needling in melasma. Dermatol Ther.2020;33(6):14358. DOI: http://dx.doi.org/10.1111/dth.14358




2020     |     www.medigraphic.com